Nephrotic Syndrome

  • Patrizia Passerini
  • Claudio Ponticelli

Abstract

The nephrotic syndrome is a clinical condition characterized by heavy proteinuria, hypoalbuminemia, hyperlipidernia, and variable degrees of edema. With the exception of minimal-change nephropathy, most primary glomerular diseases associated with the nephrotic syndrome tend to progress to renal failure. It is possible that the massive proteinuria and the lipid disorders that accompany the nephrotic syndrome may contribute to the progression (16). However, independent of renal outcome, the nephrotic state can favor thrombotic complications (7–10) and cardiovascular disease (11–17). Thus, the clinical management of nephrotic patients should take into consideration both the supportive measures aimed at reducing proteinuria and preventing the extrarenal complications and the specific pharmacological approach to the underlying disease.

Keywords

Nephrotic Syndrome Membranous Nephropathy Idiopathic Nephrotic Syndrome Minimal Change Nephrotic Syndrome Membranoproliferative Glomerulonephritis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Remuzzi G, Bertani T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 38: 384 - 394, 1990.PubMedCrossRefGoogle Scholar
  2. 2.
    Agarwal A, Nath KA: Effect of proteinuria on renal interstitium: effect of products of nitrogen metabolism. Am J Nephrol 13: 376 - 384, 1993.PubMedCrossRefGoogle Scholar
  3. 3.
    Moorhead JF, Chan MK, El Nahas M, Varghese Z: Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial disease. Lancet 2: 1309 - 1312, 1982.PubMedCrossRefGoogle Scholar
  4. 4.
    Kees-Folts D, Diamond Jr: Relationship between hyperlipidemia, lipid mediators, and progressive glomerular sclerosis in the nephrotic syndrome. Am J Nephrol 13: 365373, 1993.Google Scholar
  5. 5.
    Schlondorff D: Cellular mechanisms of lipid injury in the glomerulus. Am J Kidney Dis 22: 72 - 83, 1993.PubMedGoogle Scholar
  6. 6.
    Thomas ME, Schreiner GF: Contribution of proteinuria to progressive renal injury: consequences of tubular uptake of fatty acid bearing albumin. Am J Nephrol 13: 385 - 398, 1993.PubMedCrossRefGoogle Scholar
  7. 7.
    Cameron JS, Ogg CS, Wass VJ: Complications of the nephrotic syndrome. In: JS Cameron, RJ Glassock, eds, The Nephrotic Syndrome. M. Dekker, New York, pp 849 - 920, 1988.Google Scholar
  8. 8.
    Bellomo R, Atkins RC: Membranous nephropathy and thromboembolism: Is prophylactic anticoagulation warranted? Nephron 63: 249 - 254, 1993.PubMedCrossRefGoogle Scholar
  9. 9.
    Bernard D: Extrarenal complications of the nephrotic syndrome. Kidney Int 33: 1184 - 1202, 1988.PubMedCrossRefGoogle Scholar
  10. 10.
    Mactier R, Boulton Jones JM, Payton CD, McLay A: The natural history of membranous nephropathy in the West of Scotland. Q J Med 60: 793 - 802, 1986.PubMedGoogle Scholar
  11. 11.
    Stompfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH: A prospective study of cholesterol apolipoproteins, and the risk of myocardial infarction. N Engl J Med 325: 373 - 381, 1991.CrossRefGoogle Scholar
  12. 12.
    Kostner GM, Avogaro G, Cazzolato G, Marth E, BittoloBon G, Quinci GB: Lipoprotein(a) as a risk for myocardial infarction. Atherosclerosis 38: 51 - 61, 1981.PubMedCrossRefGoogle Scholar
  13. 13.
    Ernst E, Resch KL: Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 118: 956 - 963, 1993.PubMedCrossRefGoogle Scholar
  14. 14.
    Phillips A, Shaper AG, Whincup PH: Association between serum albumin and mortality from cardiovascular disease, cancer, and other causes. Lancet 2: 1434 - 1436, 1989.PubMedCrossRefGoogle Scholar
  15. 15.
    Berlyne GM, Mallick NP: Ischaemic heart-disease as a complication of nephrotic syndrome. Lancet 2: 399 - 400, 1969.PubMedCrossRefGoogle Scholar
  16. 16.
    Wass VJ, Jarret RJ, Chilvers C, Cameron JS: Does the nephrotic syndrome increase the risk of cardiovascular disease? Lancet 2: 664 - 667, 1979.PubMedCrossRefGoogle Scholar
  17. 17.
    Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH: The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 44: 638 - 642, 1993.PubMedCrossRefGoogle Scholar
  18. 18.
    Humphreys MH: Mechanisms and management of nephrotic edema. Kidney Int 45: 266 - 281, 1994.PubMedCrossRefGoogle Scholar
  19. 19.
    Marks MI, Drummond KN: Nephropathy and persistent proteinuria after albumin administration in the rat. Lab Invest 23: 416 - 420, 1970.PubMedGoogle Scholar
  20. 20.
    Davies DJ, Messina A, Thumwood CM, Ryan GB: Glomerular podocytic injury in protein overload proteinuria. Pathology 17: 412 - 419, 1985.PubMedCrossRefGoogle Scholar
  21. 21.
    Yoshimura A, Ideura T, Iwasaki S, Taira T, Koshikawa S: Aggravation of minimal-change nephrotic syndrome by administration of human albumin. Clin Nephrol 37: 109 - 114, 1992.PubMedGoogle Scholar
  22. 22.
    Kaysen GA: Albumin metabolism in the nephrotic syndrome: the effect of dietary protein intake. Am J Kidney Dis 12: 461 - 480, 1988.PubMedGoogle Scholar
  23. 23.
    Vriesendorp R, Donker AJM, de Zeeuw D, de Jong PE, van der Hem GK: Effects of nonsteroidal anti-inflammatory drugs on proteinuria. Am J Med 81 (Suppl 2B): 84 - 94, 1986.PubMedCrossRefGoogle Scholar
  24. 24.
    Donker AJM, Brentjens JRH, van der Hem GK, Arisz L: Treatment of the nephrotic syndrome with indomethacin. Nephron 22: 374 - 381, 1978.PubMedCrossRefGoogle Scholar
  25. 25.
    Tiggeler RGWL, Hulme B, Wijdeveld PGAB: Effect of indomethacin on glomerular permeability in the nephrotic syndrome. Kidney Int 16: 312 - 321, 1979.PubMedCrossRefGoogle Scholar
  26. 26.
    Golbetz H, Black V, Shemesh: Mechanism of the antiproteinuric effect of indomethacin in nephrotic humans. Am J Physiol 25b: F44 - F51, 1989.Google Scholar
  27. 27.
    Velosa JA, Torres VE, Donadio JB, Wagoner RV, Holley KE, Offord KP: Treatment of severe nephrotic syndrome with meclofenamate: an uncontrolled pilot study. Mayo Clin Proc 60: 586 - 592, 1985.PubMedCrossRefGoogle Scholar
  28. 28.
    Alavi N, Lianos EA, Venuto RC, Mookerjee BK, Bentzel CJ: Reduction of proteinuria by indomethacin in patients with nephrotic syndrome. Am J Kidney Dis 8: 397 - 403, 1986.PubMedGoogle Scholar
  29. 29.
    Lagrue G, Laurent J, Belghiti D, Hirbec G: Long-term non steroidal anti-inflammatory drugs improve renal survival of membranoproliferative glomerulonephritis (abstract). Proceedings of the 9th International Congress on Nephrology. Los Angeles, p 103A, 1984.Google Scholar
  30. 30.
    Vriesendorp R, de Jong PE, Sluiter WJ, de Zeeuw D, Donker AJM, van der Hem GK: The beneficial effect of indomethacin on final renal outcome in nephrotic patients (abstract). Kidney Int 30: 636 - 637, 1986.Google Scholar
  31. 31.
    Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D: Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 36: 272 - 279, 1989.PubMedCrossRefGoogle Scholar
  32. 32.
    Praga M, Hernandez E, Montoyo C, Andres A, Ruilope LM, Rodicio JL: Long-term beneficial effects of angiotensinconverting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 20: 240 - 248, 1992.PubMedGoogle Scholar
  33. 33.
    Lagrue G, Robeva R, Laurent J: Antiproteinuric effect of captopril in primary glomerular disease. Nephron 46: 99 - 100, 1987.PubMedCrossRefGoogle Scholar
  34. 34.
    Gansevoort RT, de Zeeuw D, de Jong PE: Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal disease. Am J Kidney Dis 22: 202 - 206, 1993.PubMedGoogle Scholar
  35. 35.
    Heeg JE, de Jong PE, Vriesendorp R, de Zeeuw D: Additive antiproteinuric effect of the NSAID indomethacin and the ACE inhibitor lisinopril. Am J Nephrol 10 (Suppl 1): 94 - 97, 1990.PubMedCrossRefGoogle Scholar
  36. 36.
    Kasiske BL, Velosa JA, Halstenson CE, La Belle P, Langendorfer A, Keane WF: The effect of lovastatin in hyperlipidemic patients with the nephrotic syndrome. Am J Kidney Dis 15: 8 - 15, 1990.PubMedGoogle Scholar
  37. 37.
    Thomas ME, Harris KPG, Ramaswamy C, Hattersley JM, Wheeler DC, Varghese Z, Williams JD, Walls J, Moorhead JF: Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney lnt 44: 1124 - 1129, 1993.CrossRefGoogle Scholar
  38. 38.
    D’Amico G, Gentile GM, Manna G, Fellin G, Ciceri R, Cofano F, Petrini C, Lavarda F, Perolini S, Porrini M: Effect of vegetarian soy diet on hyperlipidaemia in nephrotic syndrome. Lancet 2: 1131 - 1134, 1992.CrossRefGoogle Scholar
  39. 39.
    Edwards KDG, Schapel GJ, Neale FC: Efficacy of cholestyramine, L-tryptophan and clofibrate in the treatment of nephrotic hyperlipidemia, studied by factorial analysis. Aust NZ J Med 3: 441 - 448, 1973.Google Scholar
  40. 40.
    Valeri A, Gelfand J, Blum C, Appel GB: Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial. Am J Kidney Dis 8: 388 - 396, 1986.PubMedGoogle Scholar
  41. 41.
    Bridgman JF, Rosen SM, Thorp JM: Complications during clofibrate treatment of nephrotic syndrome hyperlipidaemia. Lancet 2: 506 - 509, 1972.PubMedCrossRefGoogle Scholar
  42. 42.
    Groggel GC, Cheung AK, Ellis-Benigni K, Wilson DE: Treatment of nephrotic hyperlipoproteinemia with gemfibrozil. Kidney Int 36: 266 - 271, 1989.PubMedCrossRefGoogle Scholar
  43. 43.
    Golper TA, Illingworth DR, Bennett WM: Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria. Am J Kidney Dis 13: 312 - 328, 1989.PubMedGoogle Scholar
  44. 44.
    Vega GL, Grundy SM: Lovastatin therapy in nephrotic hyperlipidemia: Effects on lipoprotein metabolism. Kidney Int 33: 1160 - 1168, 1988.PubMedCrossRefGoogle Scholar
  45. 45.
    Chan PCK, Robinson JD, Yeung WC, Cheng IKP, Yeung HWD, Tsang MTS: Lovastatin in glomerulonephritis patients with hyperlipidaemia and heavy proteinuria. Nephrol Dial Transplant 7: 93 - 99, 1992.PubMedGoogle Scholar
  46. 46.
    Rabelink AJ, Hene RJ, Erkelens DW, Joles JA, Koomans HA: Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. Lancet 2: 1335 - 1338, 1988.PubMedCrossRefGoogle Scholar
  47. 47.
    Corpier CL, Jones PH, Suki WN: Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac allograft recipients. DAMA 260: 239 - 241, 1988.CrossRefGoogle Scholar
  48. 48.
    Sarasin FP, Schifferli JA: Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney Int 45: 578 - 585, 1994.PubMedCrossRefGoogle Scholar
  49. 49.
    Petiti DB, Strom BL, Melmon KL: Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and haemorrhage. Am J Med 81: 255 - 259, 1986.CrossRefGoogle Scholar
  50. 50.
    Briefel GR, Marris T, Gordon DH, Nicastri AD, Friedman EA: Recurrent renal vein thrombosis consequent to membranous glomerulonephritis. Clin Nephrol 10: 32 - 37, 1978.PubMedGoogle Scholar
  51. 51.
    Cameron JS: Clinical consequences of the nephrotic syndrome. In: JS Cameron, AM Davison, JP Grunfeld, D Kerr, E Ritz, eds, Oxford Texbook of Clinical Nephrology. Oxford University Press, Oxford, pp 276 - 297, 1992.Google Scholar
  52. 52.
    Lowenstein J, Schacht RG, Baldwin DS: Renal failure in minimal change nephrotic syndrome. Am J Med 70: 227 - 233, 1981.PubMedCrossRefGoogle Scholar
  53. 53.
    Raij L, Keane WF, Leonard A, Shapiro FL: Irreversible acute renal failure in idiopathic nephrotic syndrome. Am J Med 61: 207 - 214, 1976.PubMedCrossRefGoogle Scholar
  54. 54.
    Imbasciati E, Ponticelli C, Case N, Altieri P, Bolasco F, Mihatsch MJ, Zollinger HU: Acute renal failure in idiopathic nephrotic syndrome. Nephron 28: 186 - 191, 1981.PubMedCrossRefGoogle Scholar
  55. 55.
    Schnaper HW, Robson AM: Nephrotic syndrome: minimal change disease, focal glomerulosclerosis and related disorders. In: RW Schrier, CW Gottschalk, eds, Diseases of the Kidney. Little, Brown, Boston, pp 1730 - 1784, 1992.Google Scholar
  56. 56.
    Coggins CH: Minimal change nephrosis in adults. Proceedings of the 8th International Congress on Nephrology. Karger, Basel, pp 336 - 344, 1981.Google Scholar
  57. 57.
    Arbeitsgemeinschaft fur Padiatrische Nephrologie: Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome. Lancet 1: 401 - 403, 1979.Google Scholar
  58. 58.
    Imbasciati E, Gusmano R, Edefonti A, Zucchelli P, Pozzi C, Grassi C, Della Volpe M, Perfumo F, Petrone P, Picca M, Claris-Appiani A, Pasquali S, Ponticelli C: Controlled trial of methylprednisolone pulses and low dose oral prednisone for the minimal change nephrotic syndrome. Br Med J 291: 1305 - 1308, 1985.CrossRefGoogle Scholar
  59. 59.
    Broyer M, Meyrier A, Niaudet P, Habib R: Minimal changes and focal segmental glomerular sclerosis. In: JS Cameron, AM Davison, JP Grunfeld, D Kerr, E Ritz, eds, Oxford Texbook of Clinical Nephrology. Oxford University Press, Oxford, pp 298 - 339, 1992.Google Scholar
  60. 60.
    Makker SP, Heyhann W: The idiopathic nephrotic syndrome in childhood. Am J Dis Child 127: 830 - 837, 1974.PubMedGoogle Scholar
  61. 61.
    Brodehl J: Conventional therapy for idiopathic nephrotic syndrome in children. Clin Nephrol 35 (Suppl 1): 8 - 15, 1991.Google Scholar
  62. 62.
    Leisti S, Vilska J, Hallman N: Adrenocortical insufficiency and relapsing in the idiopathic nephrotic syndrome of childhood. Pediatrics 60: 334 - 342, 1977.PubMedGoogle Scholar
  63. 63.
    Nolasco F, Cameron JS, Heywood EF, Hicks J, Ogg C, Williams DG: Adult-onset minimal-change nephrotic syndrome: a long-term follow-up. Kidney Int 29: 1215 - 1223, 1986.PubMedCrossRefGoogle Scholar
  64. 64.
    Korbet SM, Schwartz MM, Lewis EJ: Minimal change glomerulopathy of adulhood. Am J Nephrol 8: 291 - 297, 1988.PubMedCrossRefGoogle Scholar
  65. 65.
    Broyer M: La nephrose idiopatique de l’enfant et son traitement. Arch Franc Pediatr 45: 1 - 4, 1988.Google Scholar
  66. 66.
    British Association for Paediatric Nephrology: Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. Lancet 1: 1555 - 1557, 1991.Google Scholar
  67. 67.
    Weiss R: Randomized, double-blind, placebo controlled trial of levamisole for children with frequently relapsing/steroid dependent nephrotic syndrome (abstract). J Am Soc Nephrol 4: 289, 1993.Google Scholar
  68. 68.
    International Study of Kidney Disease in Children: Prospective controlled trial of cyclophosphamide therapy in children with the nephrotic syndrome. Lancet 2: 423 - 427, 1974.Google Scholar
  69. 69.
    McCrory WW, Shibuya M, Lu WH, Lewy JE: Therapeutic and toxic effects observed with different dosage programs of cyclophosphamide in treatment of steroid-responsive but frequently relapsing nephrotic syndrome. J Pediatr 82: 614 - 618, 1973.PubMedCrossRefGoogle Scholar
  70. 70.
    Cameron JS, Chantier C, Ogg CS, White RHR: A long term stability of remission in nephrotic syndrome after treatment with cyclophosphamide. Br Med J 4: 7 - 11, 1974.PubMedCrossRefGoogle Scholar
  71. 71.
    Pennisi AJ, Grunshkin CM, Lieberman E: Cyclophosphamide in the treatment of idiopathic nephrotic syndrome. Pediatrics 57: 948 - 951, 1976.PubMedGoogle Scholar
  72. 72.
    Grupe WE, Makker SP, Ingelfinger JR: Chlorambucil treatment of frequently relapsing nephrotic syndrome. N Engl J Med 295: 746 - 749, 1976.PubMedCrossRefGoogle Scholar
  73. 73.
    Arbeitsgemeinschaft fur Padatrische Nephrologie: Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with or without steroid dependance. N Engl J Med 306: 45 1454, 1982.Google Scholar
  74. 74.
    Arbeitsgemeinschft fur Padatrische Nephrologie: Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Arch Dis Child 62: 1102 - 1106, 1987.CrossRefGoogle Scholar
  75. 75.
    Etteldorf JN, West CD, Pitcock JA, Williams DL: Gonadal function, testicular histology, and meiosis following cyclophosphamide therapy in patients with nephrotic syndrome. J Pediatr 88: 206 - 212, 1976.PubMedCrossRefGoogle Scholar
  76. 76.
    Guesry P, Lenoir G, Broyer M: Gonadal effects of chlorambucil given to prepubertal and pubertal boys for nephrotic syndrome. J Pediatr 92: 299 - 303, 1978.PubMedCrossRefGoogle Scholar
  77. 77.
    Smith AG, Prentice AG, Lucie NP, Browning JD, Dagg JH, Rowan RM: Acute myelogenous leukaemia following cytotoxic therapy: five cases and a review. Q J Med 51: 227 - 240, 1982.PubMedGoogle Scholar
  78. 78.
    Baltus JAM, Boersma JW, Hartman AP, Vandenbroucke JP: The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. Ann Rheum Dis 42: 368 - 371, 1983.PubMedCrossRefGoogle Scholar
  79. 79.
    Grunwald H, Rosner F: Acute leukemia and immunosuppressive drug use: a review of patients immunosuppressive therapy for non-neoplastic diseases. Arch Intern Med 139: 461 - 466, 1979.PubMedCrossRefGoogle Scholar
  80. 80.
    Chaplin H Jr: Lymphoma in primary chronic cold hemagglutinin disease treated with chlorambucil. Arch Intern Med 944, 1987.142: 2119 - 2123, 1982.Google Scholar
  81. 81.
    Brodehl J, Ehrich JJF, Hoyer PF, Lee IJ, Oemar BS, Wonigeit K: Cyclosporine A treatment of minimal change nephrotic syndrome and focal segmental glomerulosclerosis in children. Korean J Nephrol 6: 26 - 33, 1987Google Scholar
  82. 82.
    Capodicasa G, de Santo NG, Nuzzi F, Giordano C: A in nephrotic syndrome of childhood: a 14 months experience. Int J Pediatr Nephrol 7: 69 - 72, 1986.PubMedGoogle Scholar
  83. 83.
    Niaudet P, Broyer M, Habib R: Treatment of idiopathic nephrotic syndrome with cyclosporin A (Sandimmun) in idiopathic nephrotic syndrome. Clin Nephrol 35 (Suppl 1): 48 - 60, 1991.Google Scholar
  84. 84.
    Meyrier A and Collborative Group of the Societe Nephrologie: Cyclosporin in the treatment of nephrosis. Am J Nephrol 9 (Suppl 1): 65 - 71, 1989.CrossRefGoogle Scholar
  85. 85.
    Tejani A, Butt K, Trachtman H, Suthantiran M, Rosenthal CJ, Khawar MR: Cyclosporine A induced remission of relapsing nephrotic syndrome in children. Kidney Int 33:729 -734, 1988.Google Scholar
  86. 86.
    Ponticelli C, Rivolta E: Cyclosporin in minimal-change glomerulopathy and in focal segmental glomerular sclerosis. Am J Nephrol 10 (Suppl 1): 105 - 109, 1990.PubMedCrossRefGoogle Scholar
  87. 87.
    Niaudet P and the French Society of Paediatric Nephrology: Comparison of cyclosporin and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Pediatr Nephrol 6: 1 - 3, 1992.CrossRefGoogle Scholar
  88. 88.
    Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, Lama G, Zacchello G, Confalnieri R, Altieri P,Bettinelli A, Maschio G, Cinotti GA, Fuiano G, Schena FP, Castellani A, Della Casa-Alberighi O: Cyclosporine vs. cyclophosphamide for patients with steroid-dependent/frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transpathy. N Engl J Med 320: 8 - 13, 1989.PubMedCrossRefGoogle Scholar
  89. 89.
    Collaborative Study Group of Sandimmun in Nephrotic Syndrome: Safety and tolerability of cyclosporin A (Sand immun) in idiopathic nephrotic syndrome. Clin Nephrol 35 (Suppl 1): 48 - 60, 1991.Google Scholar
  90. 90.
    Feutren G, Mihatsch M: Risk factors for cyclosporine-induced nephropathy in patients with autoimmune disease. N Engl J Med 326: 1654 - 1660, 1992.PubMedCrossRefGoogle Scholar
  91. 91.
    Meyrier A, Condamin M-C, Broneer D, and the Collabora tive Group of the French Society of Nephrology: Treatment of membranous of adult idiopathic nephrotic syndrome with cyclosporin A: nephropathy. Kidney Int 29: 927 - 940, 1986.CrossRefGoogle Scholar
  92. 92.
    Schwartz MM, Korbet SM: Primary focal segmental glomerulosclerosis: Pathology, histological variants, and Transplant 4: 525 - 529, 1989.Google Scholar
  93. 93.
    Ponticelli C, Fogazzi GB, Passerini P: Pharmacological treatment of chronic glomerulonephritis. In: G Remuzzi, T Bertani, eds, Drugs and Kidney. Raven Press, New York, pp. 301:1301-1306, 1979.Google Scholar
  94. 94.
    Schena PF, Cameron JS: Treatment of proteinuric idiopathic glomerulonephritides in adults: a retrospective study. Am J Med 85:315-326, 1988. syndrome in adults. Q J Med 74: 1313 - 1356, 1990.Google Scholar
  95. 95.
    Saint-Hillier Y, Morel-Maroger L, Woodrow D, Richet G:Focal and segmental hyalinosis. Adv Nephrol 5: 67 - 88, 1975.Google Scholar
  96. 96.
    Pei Y, Cattran D, Delmore T, Katz A, Lang A, Rance P: Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Am J Med 82: 938 - 944, 1987.PubMedCrossRefGoogle Scholar
  97. 97.
    Korbet SM, Schwartz MM, Lewis EJ: The prognosis of focal segmental glomerulosclerosis of adulthood. Medicine 5: 304 - 311, 1986.Google Scholar
  98. 98.
    Nanra RS, Jones BF, Trevillian PR: Primary focal glomerular sclerosis (PFGS). Factors influencing outcome in 89 patients (abstract). Proceedings of the 11th International Congress on Nephrology, Tokyo, p. 6, 1990.Google Scholar
  99. 99.
    Banfi G, Moriggi M, Sabadini E, Fellin G, D’Amico G, Ponticelli C: The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerul osclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol 36: 53 - 59, 1991.PubMedGoogle Scholar
  100. 100.
    Mendoza SA, Reznik VM, Griswold WR, Krensky AM,Yorgin PD, Tune BM: Treatment of steroid-resistant focal glomerulosclerosis with pulse methylprednisolone and alkyidiopathic nephrotic syndrome 65 - 71, 1989.Google Scholar
  101. 101.
    Waldo FB, Benfield MR, Kohaut EC: Methylprednisolone treatment of patients with steroid-resistant nephrotic syndrome. Pediatr Nephrol 6: 503 - 505, 1992.PubMedCrossRefGoogle Scholar
  102. 102.
    Ponticelli C: Treatment of nephrotic syndrome with cyclosporin A. J Autoimmunol 5 (Suppl A): 315 - 324, 1992.CrossRefGoogle Scholar
  103. 103.
    Miller C, Feutren G, Schiess W, von Graffenried B:Serum creatinine in cyclosporin-induced remission of steroid resistant nephrotic syndrome (letter). Lancet 2: 1352 1990.CrossRefGoogle Scholar
  104. 104.
    Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E,Rinaldi S, Ghio L, Lusvarghi E, Gusmano R, Locatelli F,Pasquali S, Castellani A, Della Casa-Alberighi O: A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 43: 1377 - 1384, 1993.PubMedCrossRefGoogle Scholar
  105. 105.
    Ponticelli C, Zucchelli P, Passerini P, Cagnoli L, Cesana B, Pozzi C, Pasquali S, Imbasciati E, Grassi C, Redaelli B,Sasdelli M, Locatelli F: A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 320: 8 - 13, 1989.PubMedCrossRefGoogle Scholar
  106. 106.
    Cameron JS: Pathogenesis and treatment of membranous nephropathy. Kidney Int 15: 88 - 103, 1979.PubMedCrossRefGoogle Scholar
  107. 107.
    Wehrmann M, Bohle A, Bogenschutz O, Eissele R,Freislederer A, Ohlschlegel C, Schumm G, Batz C, Gartner H-V: Long-term prognosis of chronic idiopathic membranous glomerulonephritis. An analysis of 334 cases with particular regard to tubulo-interstitial changes. ClinNephrol 31: 67 - 76, 1989.Google Scholar
  108. 108.
    Ponticelli C: Prognosis and treatment of membranous nephropathy. Kidney Int 29: 927 - 940, 1986.PubMedCrossRefGoogle Scholar
  109. 109.
    Passerini P, Pasquali S, Cesana B, Zucchelli P, Ponticelli C:Long-term outcome of patients with membranous nephropathy after complete remission of proteinuria. Nephrol DialTransplant 4: 525 - 529, 1989.Google Scholar
  110. 110.
    Collaborative Study of the Adult Idiopathic Nephrotic Syndrome: A controlled study of short-term prednisone treatment in adults with membranous nephropathy. N Engl J Med 301: 1301 - 1306, 1979.CrossRefGoogle Scholar
  111. 111.
    Cameron JS, Healy MJR, Adu D: The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephritic syndrome in adults. Q J Med 74: 1313 - 1356, 1990.Google Scholar
  112. 112.
    Cattran DC, Delmore T, Roscoe J, Cole E, Cardella C, Charron R, Ritchie S: A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N Engl J Med 320: 210 - 215, 1989.PubMedCrossRefGoogle Scholar
  113. 113.
    Donadio JV Jr, Holley KE, Anderson CF, Taylor WF: Controlled trial of cyclophosphamide in idiopathic membranous nephropathy. Kidney Int 6: 431 - 439, 1974.PubMedCrossRefGoogle Scholar
  114. 114.
    Lagrue G, Bernard D, Bariety J, Druet P, Guenel J: Traitement par le chlorambucil et l’azathioprine dans les glomerulonephrites primitives: résultats d’une étude côntrolée. J Urol Nephrol 81: 655 - 672, 1975.Google Scholar
  115. 115.
    Tiller DJ, Clarkson AR, Matthew T, Thompson N, Row G, Laver G, Hobbes J, Seymour A: A prospective randomized trial in the use of cyclophosphamide, dipyridamole and warfarin in membranous and mesangiocapillary glomerulonephritis. In: W Zurukzoglu, M Papadimitriou,M Pyrpasopoulos, M Sion, C Zamboulis, eds, Proceedings of the 8th International Congress on Nephrology, University Studio and Karger, Tessaloniki and Basel, pp 345 - 354, 1981.Google Scholar
  116. 116.
    Murphy BF, McDonald I, Fairley KF, Kincaid-Smith PS: Randomized controlled trial of cyclophosphamide, warfarin and dipyridamole in idiopathic membranous nephropathy. Clin Nephrol 37: 229 - 234, 1992.PubMedGoogle Scholar
  117. 117.
    Ponticelli C, Zucchelli P, Passerini P, Cesana B, and the Italian Idiopathic Membranous Nephropathy Treatment Study Group: Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. N Engl J Med 327: 599603, 1992.Google Scholar
  118. 118.
    De Santo NG, Capodicasa G, Giordano C: Treatment of idiopathic membranous nephropathy unresponsive to methylprednisolone and chlorambucil with cyclosporin. Am J Nephrol 7: 74 - 76, 1987.CrossRefGoogle Scholar
  119. 119.
    Rostoker G, Belghiti D, Ben Maadi A, Remi P, Lang P, Weil B, Lagrue G: Long-term cyclosporin A therapy for severe idiopathic membranous nephropathy. Nephron 63: 335 - 341, 1993.PubMedCrossRefGoogle Scholar
  120. 120.
    Zietse R, Weening GJ, Kramer P, Mulder P, Schalekamp MADH, Weinar W: Contrasting response to cyclosporin in refractory nephrotic syndrome. Clin Nephrol 31: 22 - 25, 1989.PubMedGoogle Scholar
  121. 121.
    Palla R, Cirami C, Panichi V, Bianchi AM, Parrini M, Grazi G: Intravenous immunoglobulin therapy of membranous nephropathy: efficacy and safety. Clin Nephrol 35: 98 - 104, 1991.PubMedGoogle Scholar
  122. 122.
    Rault R, Piraino B, Johnston JR, Oral A: Pulmonary and renal toxicity of intravenous immunoglobulin. Clin Nephrol 36: 83 - 86, 1991.PubMedGoogle Scholar
  123. 123.
    Short CD, Solomon LR, Gokal R, Mallick MP: Methylprednisolone in patients with membranous nephropathy and declining renal function. Q J Med 65: 929 - 940, 1987.PubMedGoogle Scholar
  124. 124.
    Williams PS, Bone JM: Immunosuppression can arrest progressive renal failure due to idiopathic membranous glomerulonephritis. Nephrol Dial Transplant 4: 181 - 186, 1989.PubMedGoogle Scholar
  125. 125.
    Mathieson PW, Turner AN, Maidment CGH, Evans DJ, Rees AJ: Prednisolone and chlorambucil treatment in idiopathic membranous nephropathy with deteriorating renal function. Lancet ií: 869 - 872, 1988.Google Scholar
  126. 126.
    Bruns FJ, Adler S, Fraley DS, Segel DP: Sustained remission of membranous glomerulonephritis after cyclophosphamide and prednisone. Ann Intern Med 114: 725 - 730, 1991.PubMedCrossRefGoogle Scholar
  127. 127.
    Jindal K, West M, Bear R, Goldstein M: Long-term benefits of therapy with cyclophosphamide and prednisone in patients with membranous glomerulonephritis and impaired renal function. Am J Kidney Dis 1: 61 - 67, 1992.Google Scholar
  128. 128.
    Falk RJ, Hogan SL, Muller KE, Jennette JC and the Glomerular Disease Collaborative Network: Treatment of progressive membranous glomerulopathy. A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. Ann Intern Med 116: 438 - 445, 1992.PubMedCrossRefGoogle Scholar
  129. 129.
    Reichert UM, Koene RAP, Wetzels JFM: Chlorambucil but not pulse cyclophosphamide reverses the deterioration of renal function in patients with membranous glomerulopathy (abstract). J Am Soc Nephrol 4: 285, 1993.Google Scholar
  130. 130.
    Pei Y, Cattran D, Greenwood C: Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 42: 960 - 966, 1992.PubMedCrossRefGoogle Scholar
  131. 131.
    Donadio JV Jr, Torres VE, Velosa JA, Wagoner RD, Holley KE, Okamura M, Ilstrup DM, Chu CP: Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int 33: 708 - 715, 1988.PubMedCrossRefGoogle Scholar
  132. 132.
    Donadio JV, Offord KP: Reassessment of treatment results in membranoproliferative glomerulonephritis, with emphasis on life-table analysis. Am J Kidney Dis 14: 445 - 451, 1989.PubMedGoogle Scholar
  133. 133.
    McEnery PT, McAdams Ai, West CD: The effect of prednisone in a high-dose, alternate-day regimen on the natural history of idiopathic membranoproliferative glomerulonephritis. Medicine (Baltimore) 64: 401 - 424, 1985.Google Scholar
  134. 134.
    West CD: Childhood membranoproliferative glomerulonephritis: an approach to management. Kidney Int 29: 1077 1093, 1986.Google Scholar
  135. 135.
    A Report of the International Study of Kidney Disease in Children: Alternate day steroid therapy in membranoproliferative glomerulonephritis: a randomized controlled clinical trial (abstract). Kidney Int 21: 150, 1982.Google Scholar
  136. 136.
    Ford DM, Briscoe DM, Shanley PF, Lum GM: Childhood membranoproliferative glomerulonephritis type I: limited steroid therapy. Kidney Int 41: 1606 - 1612, 1992.PubMedCrossRefGoogle Scholar
  137. 137.
    Lagrue G, Laurent J, Belghiti D: Renal survival in membranoproliferative glomerulonephritis (MPGN): role of long-term treatment with non-steroidal antiinflammatory drugs (NSAID). Int Urol Nephrol 20: 669 - 677, 1988.PubMedCrossRefGoogle Scholar
  138. 138.
    Vanrenterghem Y, Roels L, Verberckoes R, Michielsen P: Treatment of chronic glomerulonephritis with a combination of indomethacin and cyclophosphamide. Clin Nephrol 4: 218222, 1975.Google Scholar
  139. 139.
    Kincaid-Smith P: The treatment of chronic mesangiocapillary (membranoproliferative) glomerulonephritis with impaired renal function. Med J Aust 2: 587 - 592, 1972.PubMedGoogle Scholar
  140. 140.
    Cattran DC, Cardella CJ, Roscoe JM, Charron RC, Rance PC, Ritchie SM, Corey PN: Results of a controlled drug trial in membranoproliferative glomerulonephritis. Kidney Int 27: 436 - 441, 1985.PubMedCrossRefGoogle Scholar
  141. 141.
    Donadio JV Jr, Anderson CF, Mitchell JC III, Holley KE, Ilstrup DM, Fuster V, Chesebro JH: Membranoproliferative glomerulonephritis: a prospective clinical trial of platelet-inhibiting therapy. N Engl J Med 310: 1421 - 1426, 1984.PubMedCrossRefGoogle Scholar
  142. 142.
    Mustonen J, Pasternack A, Rantala I: The nephrotic syndrome in IgA glomerulonephritis: response to corticosteroid therapy. Clin Nephrol 20: 172 - 176, 1983.PubMedGoogle Scholar
  143. 143.
    Lai KN, Lai FM, Ho CP, Chan KW: Corticosteroid therapy in IgA nephropathy with nephrotic syndrome:a long-term controlled trial. Clin Nephrol 26:174-180,Google Scholar
  144. 144.
    Southwest Pediatric Nephrology Study Group: Association of IgA nephropathy with steroid-responsive nephrotic syndrome. Am J Kidney Dis 3: 157 - 164, 1985.Google Scholar
  145. 145.
    DAmico G, Colasanti G, Barbiano DI, Belgiojoso G, Fellin G, Ragni A, Egidi F, Radaelli L, Fogazzi GB, Ponticelli C, Minetti L: Long-term follow-up of IgA mesangial nephro pathy. Clinico-histological study of 374 patients. Semin Nephrol 7: 355 - 358, 1987.PubMedGoogle Scholar
  146. 146.
    Welch TR, Fryer C, Shely E: Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis. J Pediatr 121: 474 - 477, 1992.PubMedCrossRefGoogle Scholar
  147. 147.
    Lai KN, Lai FM, Li PK, Vallance-Owen J: Cyclosporin treatment of IgA nephropathy: a short-term controlled trial. Br Med J 295: 1165 - 1168, 1987.CrossRefGoogle Scholar
  148. 148.
    Schena PF, Montenegro M, Scivittaro V: Metaanalysis of randomized controlled trials with patients with primary IgA ephropathy or Berger disease. Nephrol Dial Transplant Nephrol 7:355-358, 1987. (Suppl 1): 47 - 52, 1990.Google Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Patrizia Passerini
    • 1
  • Claudio Ponticelli
    • 1
  1. 1.Instituto di Ricovero e Cura a Carattere Scientifico, Divisione di Nefrologia e Dialisi-Pad. CroffOspedale Maggiore di MilanoMilanoItaly

Personalised recommendations